[1]井山泉a,梁莉萍b,刘林林a,等.胶质瘤组织中TRIP4 和DDIT4 水平表达及其与临床病理特征和预后的关系[J].现代检验医学杂志,2024,39(02):18-22+128.[doi:10.3969/j.issn.1671-7414.2024.02.004]
　JING Shanquana,LIANG Lipingb,LIU Linlina,et al.Expression of TRIP4 and DDIT4 in Glioma Tissue and Their Relationship with Clinical Pathological Parameters and Prognosis[J].Journal of Modern Laboratory Medicine,2024,39(02):18-22+128.[doi:10.3969/j.issn.1671-7414.2024.02.004]
点击复制

胶质瘤组织中TRIP4 和DDIT4 水平表达及其与临床病理特征和预后的关系()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第39卷
期数:
2024年02期
页码:
18-22+128
栏目:
论著
出版日期:
2024-03-31

文章信息/Info

Title:
Expression of TRIP4 and DDIT4 in Glioma Tissue and Their Relationship with Clinical Pathological Parameters and Prognosis
文章编号:
1671-7414（2024）02-018-06
作者:
井山泉a; 梁莉萍b; 刘林林a; 李 辉a; 李聪慧a; 徐丽峰a
（河北医科大学第一医院 a. 神经外科；b. 介入治疗科，石家庄 050031）
Author(s):
JING Shanquana;  LIANG Lipingb;  LIU Linlina;  LI Huia;  LI Conghuia;  XU Lifenga
（a. Department of Neurosurgery； b. Department of Interventional Therapy, the First Hospital of Hebei Medical University, Shijiazhuang 050031, China）
关键词:
胶质瘤; 甲状腺激素受体结合蛋白4; DNA 损伤诱导转录因子4
分类号:
R739.4；R730.43
DOI:
10.3969/j.issn.1671-7414.2024.02.004
文献标志码:
A
摘要:
目的　研究胶质瘤组织中甲状腺激素受体结合蛋白4(thyroid hormone receptor interacting protein 4，TRIP4) 和DNA 损伤诱导转录因子4(DNA damage inducing transcription factor 4，DDIT4) 水平表达及其与临床病理特征和预后的关系。方法　选取2018 年2 月～ 2019 年2 月河北医科大学第一医院收治的94 例胶质瘤患者为研究对象。应用免疫组织化学法检测组织中TRIP4 和DDIT4 蛋白表达。比较不同临床病理特征脑胶质瘤组织中TRIP4 和DDIT4 蛋白表达。采用Kaplan-Meier 生存曲线分析不同TRIP4 和DDIT4 蛋白表达胶质瘤患者生存预后的差异。单因素和多因素COX 回归分析影响胶质瘤患者生存预后的因素。结果　胶质瘤组织中TRIP4（68.09%）和DDIT4（65.96%）蛋白阳性率高于瘤旁组织（13.83%，10.64%），差异具有统计学意义（χ2=57.212，60.866，均P ＜ 0.05）。胶质瘤组织中TRIP4 与DDIT4 蛋白表达呈显著正相关性（r=0.722，P ＜ 0.05）。WHO 分级Ⅲ级、肿瘤直径≥ 3cm 胶质瘤组织中TRIP4 和DDIT4 蛋白阳性率均高于WHO 分级I ～ II 级、肿瘤直径＜ 3cm 胶质瘤组织，差异具有统计学意义（χ2=6.393 ～ 14.754，均P<0.05）。TRIP4 阳性表达组和阴性表达组三年总体生存率分别为37.50%（24/64），66.67%（20/30），TRIP4 阳性表达组三年累积生存率低于阴性表达组，差异具有统计学意义（Log-rankχ2=5.949，P=0.015）。DDIT4 阳性表达组和阴性表达组三年总体生存率分别为37.10%（23/62），70.00%（21/30），DDIT4 阳性表达组三年累积生存率低于阴性表达组，差异具有统计学意义（Log-rankχ2=7.642，P=0.006）。肿瘤直径≥ 3cm（HR=1.614，P=0.000），WHO 分级Ⅲ级（HR=1.790，P=0.000），TRIP4 阳性表达（HR=1.665，P=0.000），DDIT4 阳性表达（HR=1.476，P=0.000）是影响胶质瘤患者生存预后的独立危险因素。结论　胶质瘤组织中TRIP4 和DDIT4 蛋白表达升高，两者与肿瘤直径及WHO 分级相关，是潜在的评估胶质瘤预后的肿瘤标志物。
Abstract:
Objective　To study the expression of thyroid hormone receptor binding protein 4 (TRIP4) and DNA damage inducing transcription factor 4 (DDIT4) in glioma tissue and their relationship with clinical pathological characteristics and prognosis. Methods　94 glioma patients admitted to the First Hospital of Hebei Medical University from February 2018 to February 2019 were selected as the research subjects. The expression of TRIP4, DDIT4 proteins in tissues were detected by immunohistochemistry. The relationship between the expression of TRIP4, DDIT4 proteins in glioma tissues and clinical pathological characteristics were compared. The differences in survival prognosis of glioma patients with different levels of TRIP4, DDIT4 protein expression were analyzed by Kaplan-Meier survival curve. Univariate and multivariate COX regression analysis was conducted to analyze the factors affecting the survival prognosis of glioma patients. Results　The positive rates of TRIP4 (68.09%), DDIT4 (65.96%) proteins in glioma tissues were higher than those in adjacent tissues(13.83%, 10.64%), with statistically significant differences (χ2=57.212, 60.866, all P<0.05). There was a significant positive correlation between TRIP4 and DDIT4 protein expression in glioma tissues (r=0.722, P<0.05). The positive rates of TRIP4 (83.64% vs 46.15%, 80.00% vs 51.28%) and DDIT4 (80.00% vs 46.15%, 76.36% vs 51.28%) proteins in glioma tissues with tumor diameter ≥ 3cm, WHO grade III were significantly higher than those in tissues with tumor diameter ＜ 3cm, WHO grade I ～ II (χ2=6.393 ～ 14.754, P<0.05). The 3-year overall survival rates of the TRIP4 positive and negative expression groups were 37.50% (24/64) and 66.67% (20/30), respectively. The 3-year cumulative survival of the TRIP4 positive expression group was significantly lower than that in the TRIP4 negative expression group (Log-rank χ2=5.949，P=0.015）. The 3-year overall survival rate of DDIT4 positive and negative expression group was 37.10% (23/62) and 70.00% (21/30), respectively. The 3-year cumulative survival of the DDIT4 positive expression group was significantly lower than that in the DDIT4 negative expression group (Log-rank χ2=7.642， P=0.006). Tumor diameter ≥ 3cm (HR=1.614, P=0.000), WHO grade III (HR=1.790, P=0.000), positive TRIP4 (HR=1.665, P=0.000) and positive DDIT4 (HR=1.476, P=0.000) were independent risk factors affecting the survival prognosis of glioma patients. Conclusion　The expression of TRIP4 and DDIT4 protein in glioma tissue was increased. Both of them were related to tumor diameter and WHO grade, and are potential tumor markers for survival prognosis of glioma.

参考文献/References:

[1] BAI J, VARGHESE J, JAIN R. Adult glioma WHO classification update, genomics, and imaging: what the radiologists need to know[J]. Topics in Magnetic Resonance Imaging, 2020, 29(2): 71-82.
[2] YANG Keyang, WU Zhijing, ZHANG Hao, et al. Glioma targeted therapy: insight into future of molecular approaches[J]. Molecular Cancer, 2022, 21(1): 39.
[3] BAO Zhaoshi, WANG Yongzhi, WANG Qiangwei, et al. Intratumor heterogeneity, microenvironment, and mechanisms of drug resistance in glioma recurrence and evolution[J]. Frontiers of Medicine, 2021, 15(4):551-561.
[4] DEMBOUR A, DESTR?E A, DEPREZ M, et al. ASC1 complex related conditions: Two novel paediatric patients with TRIP4 pathogenic variants and review of literature[J]. European Journal of Medical Genetics,2022, 65(4): 104469.
[5] CHE Yilin, LI Yizhuo, ZHENG Fufu, et al. TRIP4 promotes tumor growth and metastasis and regulates radiosensitivity of cervical cancer by activating MAPK,PI3K/AKT, and hTERT signaling [J]. Cancer Letters,2019, 452: 1-13.
[6] WANG Sheng, XIE Liji, XIE Zhixun, et al. Dynamic changes in the expression of interferon-stimulated genes in joints of SPF chickens infected with avian reovirus [J]. Frontiers in Veterinary Science, 2021, 8: 618124.
[7] DU Feng, SUN Lina, CHU Yi, et al. DDIT4 promotes gastric cancer proliferation and tumorigenesis through the p53 and MAPK pathways[J]. Cancer Commun (Lond), 2018, 38(1): 45.
[8] 中国抗癌协会脑胶质瘤专业委员会. 中国抗癌协会脑胶质瘤整合诊治指南( 精简版)[J]. 中国肿瘤临床,2022, 49(16): 811-818 China Anti-Cancer Association Committee of Glioma. Integrated diagnosi s and treatment guidelines for gliomas of the Chinese anti cancer association(simplified edition)[J]. Chinese Journal of Clinical Oncology, 2022, 49(16): 811-818.
[9] 秦君翔, 黄锦峰, 袁学刚, 等．miR-124 靶向调控CMTM6 增强CIK 对胶质瘤细胞杀伤效应机制研究[J]. 现代检验医学杂志, 2023, 38(1): 94-99. QIN Junxiang, HUANG Jinfeng, YUAN Xuegang,et al. Study on the mechanism of miR-124 targeted regulating of CMTM6 to enhance the cytotoxic effect of CIK on glioma cells[J]. Journal of Modern Laboratory Medicine, 2023, 38(1): 94-99.
[10] JIA Junqiao, HILAL T, BOHNSACK K E, et al. Extended DNA threading through a dual-engine motor module of the activating signal co-integrator 1 complex[J]. Nature Communications, 2023, 14(1): 1886.
[11] CHENG Lei, PENG Renjun, GUO Pin, et al. A HIF1A/miR-485-5p/SRPK1 axis modulates the aggressiveness of glioma cells upon hypoxia[J]. Experimental Cell Research, 2021, 402(1): 112547.
[12] FANG Xiaoyu, XIE Min, LIU Xiansheng, et al. REDD1 gene knockout alleviates vascular smooth muscle cell remodeling in pulmonary hypertension[J]. American Journal of Translational Research, 2022, 14(3): 1578-1591.
[13] ZHU Yingping, XU Leilai, MA Weirong, et al. Research on radiosensitivity of the protein kinase B signaling pathway in cervical cancer [J]. Computational and Mathematical Methods in Medicine, 2021, 2021:6350038.
[14] MIAO Zhifeng, SUN Jingxu, ADKINS-THREATS M,et al. DDIT4 licenses only healthy cells to proliferate during injury-induced metaplasia[J]. Gastroenterology,2021, 160(1): 260-271, e10.
[15] NAKI M, GOURDOMICHALI O, ZONKE K, et al. APEX2-mediated proximity labeling resolves the DDIT4-interacting proteome[J]. International Journal of Molecular Sciences, 2022, 23(9): 5189.
[16] DING Fadian, HONG Xiaoping, FAN Xiangqun, et al. DDIT4 novel mutations in pancreatic cancer [J].Gastroenterology Research and Practice, 2021, 2021:6674404.
[17] HU Tao, WANG Fengmiao, HAN Guangkui. LncRNA PSMB8-AS1 acts as ceRNA of miR-22-3p to regulate DDIT4 expression in glioblastoma [J]. Neuroscience Letters, 2020, 728: 134896.
[18] L? Xiaoqian, HU Yuting, WANG Lina, et al. DDIT4 mediates the proliferation-promotive effect of IL-34 in human monocytic leukemia cells[J]. Blood Sci, 2021,3(2): 48-56.
[19] ZHANG Chunyan, TANG Bingxiang, HU Jianping, et al. Neutrophils correlate with hypoxia microenvironment and promote progression of non-small-cell lung cancer[J]. Bioengineered, 2021, 12(1): 8872-8884.
[20] FOLTYN M, LUGER A L, LORENZ N I, et al. The physiological mTOR complex 1 inhibitor DDIT4 mediates therapy resistance in glioblastoma[J]. British Journal of Cancer, 2019, 120(5): 481-487.
[21] LI Wenyang, HU Sheng, TIAN Chunfang, et al.TRIP4 transcriptionally activates DDIT4 and subsequent mTOR signaling to promote glioma progression [J].Free Radical Biology and Medicine, 2021, 177: 31-47.

相似文献/References:

[1]秦君翔,黄锦峰,袁学刚,等.miR-124 靶向调控CMTM6 增强CIK 对胶质瘤细胞杀伤效应机制研究[J].现代检验医学杂志,2023,38(01):94.[doi:10.3969/j.issn.1671-7414.2023.01.018]
　QIN Jun-xiang,HUANG Jin-feng,YUAN Xue-gang,et al.Study on the Mechanism of miR-124 Targeted Regulating of CMTM6 to Enhance the Cytotoxic Effect of CIK on Glioma Cells[J].Journal of Modern Laboratory Medicine,2023,38(02):94.[doi:10.3969/j.issn.1671-7414.2023.01.018]

备注/Memo

备注/Memo:
基金项目：河北省医学科学研究重点项目（编号：20160702）：不同临床病理特征脑胶质瘤组织中TR1R4，DD1T4 蛋白表达及预后研究。
作者简介：井山泉（1982-），男，硕士，副主任医师，从事脑胶质瘤方向的研究，E-mail：jingshanquan001@163.com。
通讯作者：徐丽峰（1984-），男，硕士，副主任医师，从事脑胶质瘤方向的研究，E-mail：xulf200@163.com。
更新日期/Last Update: 2024-03-15